emu Pivotal Trial Recruitment Surpasses 200 Patients
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The trial aims to support FDA clearance for the emu point-of-care brain scanner, which is designed for rapid stroke diagnosis. No device-related adverse events have been reported, and the emu has been successfully integrated into hospital workflows. Upcoming milestones include continued site activations and a target for full trial enrollment in early next year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- Appendix 4E & Annual Report to 30 June 2026
- FY26 Results Presentation
- Appendix 4G & Corporate Governance Statement
- Change of Registered Office Address
- Aeromedical Study De-Risks Rural & Remote Stroke Use Cases
Later from EMvision Medical Devices
- emu Regional Benefits Study Advancing
- Notification regarding unquoted securities - EMV
- First Responder Successfully Trialled with MSU
- $4.3m Non-Dilutive R&D Tax Rebate Received
- Date of AGM & Closing Date of Director Nominations
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices